Parkinson’s disease is one of the most common neurodegenerative disorders. According to the World Health Organization, more than 8.5 million people worldwide were living with Parkinson’s disease in 2019, and its global prevalence has doubled over the past 25 years.

At Bay Biosciences, we provide high-quality Parkinson’s disease PBMC samples, serum, plasma, and other human biospecimens for Parkinson’s disease research.

These samples support studies involving neuroinflammation, immune-cell activity, biomarker discovery, disease progression, and therapeutic development.

Understanding Parkinson’s Disease

Parkinson’s disease is a progressive neurological disorder that primarily affects movement. It develops when dopamine-producing neurons in a part of the brain called the substantia nigra become damaged or die.

Dopamine is a neurotransmitter that helps control movement, coordination, motivation, and several other functions.

As dopamine-producing neurons are lost, the brain becomes less able to regulate smooth and coordinated muscle activity.

Parkinson’s disease can also affect sleep, mood, cognition, digestion, speech, and other non-motor functions.

Although the disease is more common in older adults, younger individuals can also develop the condition.

Symptoms of Parkinson’s Disease (PD)

The symptoms of Parkinson’s disease vary between individuals and may develop gradually. Some non-motor symptoms can appear years before noticeable movement problems.

Early symptoms may include:

The major motor symptoms of Parkinson’s disease include:

  • Resting tremor
  • Slowness of movement, also called bradykinesia
  • Muscle stiffness or rigidity
  • Problems with balance and posture
  • Difficulty walking
  • Reduced arm swinging
  • Freezing during movement
  • Changes in gait

The presence and severity of symptoms differ from patient to patient.

Therefore, researchers use well-characterized Parkinson’s disease research samples to investigate biological differences between individuals and disease stages.

Causes of Parkinson’s Disease (PD)

The exact cause of Parkinson’s disease is not fully understood.

However, research suggests that genetic, environmental, and biological factors may contribute to the development of the condition.

Firstly, abnormal accumulation of the protein alpha-synuclein is a major area of Parkinson’s disease research. Alpha-synuclein can form clumps known as Lewy bodies, which are commonly observed in the brains of people with Parkinson’s disease.

Secondly, mitochondrial dysfunction may contribute to neuronal damage. Mitochondria produce energy for cells, and impaired mitochondrial activity may increase oxidative stress and reduce the ability of neurons to survive.

Thirdly, neuroinflammation may play a role in disease progression.

Finally, genetic changes may increase susceptibility to Parkinson’s disease in some individuals.

Risk Factors for Parkinson’s Disease (PD)

Several factors may increase the likelihood of developing Parkinson’s disease.

Firstly, age is one of the strongest risk factors. Parkinson’s disease is more common among older adults, although young-onset cases also occur.

Secondly, sex may influence risk. Parkinson’s disease is generally diagnosed more frequently in men than women.

Thirdly, family history may increase susceptibility. Individuals with close relatives who have

Furthermore, exposure to some environmental substances, including pesticides, solvents, and air pollution, has been investigated as a possible risk factor.

Finally, head injury and other neurological or biological factors may be associated with

Parkinson’s disease in some studies.

Diagnosis of Parkinson’s Disease (PD)

There is no single blood test that confirms Parkinson’s disease. Diagnosis is generally based on the patient’s medical history, symptoms, and neurological examination.

Firstly, a healthcare provider may assess movement, muscle tone, balance, coordination, and walking patterns.

Secondly, the physician may review non-motor symptoms, medication history, family history, and the progression of symptoms.

Thirdly, imaging tests such as MRI or CT scans may be used to rule out other neurological conditions.

A dopamine transporter scan may sometimes support the assessment when the diagnosis is uncertain, although it does not independently confirm Parkinson’s disease.

Researchers are also investigating blood-based biomarkers, alpha-synuclein detection methods, inflammatory markers, and other molecular tools that may improve early detection and disease classification.

These investigations create a need for well-characterized human biospecimens for Parkinson’s research.

Treatment of Parkinson’s Disease (PD)

There is currently no cure for Parkinson’s disease.

Treatment focuses on managing symptoms, maintaining mobility, and supporting quality of life.

Firstly, levodopa is commonly used to improve movement symptoms. It is often combined with carbidopa, which helps increase the amount of levodopa that reaches the brain.

Secondly, dopamine agonists may imitate the effects of dopamine in the brain. Examples include pramipexole and ropinirole.

Thirdly, monoamine oxidase-B inhibitors may help reduce the breakdown of dopamine.

Other medications may be used to manage tremor, dyskinesia, sleep problems, depression, or other symptoms.

Furthermore, physical therapy, occupational therapy, speech therapy, exercise, and balance training may help individuals maintain function and independence.

Applications of Parkinson’s Disease PBMC Samples

Parkinson’s disease PBMC samples are valuable research materials because they contain immune cells obtained from the peripheral blood of patients diagnosed with Parkinson’s disease.

Peripheral blood mononuclear cells include lymphocytes and monocytes.

These cell populations can support investigations into immune activity, inflammation, cellular signaling, and disease-associated biological changes.

PBMC Samples for Neurodegenerative Research Samples

PBMC samples for neurodegenerative research may be used to investigate the relationship between peripheral immune responses and neurological disorders.

Researchers may examine immune-cell activation, cytokine production, gene expression, cellular metabolism, and inflammatory signaling in Parkinson’s disease and other neurodegenerative conditions.

PBMCs may also be compared between patients, healthy controls, and individuals with different disease stages.

These comparisons can help researchers investigate biological differences associated with disease progression.

Frequently Asked Questions

What types of Parkinson’s disease research samples are available?

Parkinson’s disease research samples may include PBMCs, serum, plasma, peripheral whole blood, and other human biospecimens.

What are human biospecimens for Parkinson’s research used to investigate?

Human biospecimens for Parkinson’s research may support studies of neuroinflammation, immune responses, alpha-synuclein biology, genetic factors, biomarkers, disease progression, and drug development.

Are Parkinson’s disease PBMC samples suitable for neurodegenerative disease research?

Yes. Parkinson’s disease PBMC samples may support broader neurodegenerative disease research, especially studies investigating peripheral immune responses, inflammation, cellular signaling, and biological differences between neurological disorders.

Supporting Your Research with Bay Biosciences

At Bay Biosciences, we provide high-quality Parkinson’s disease PBMC samples and other human biospecimens to support neurodegenerative disease research, biomarker discovery, immunological studies, and drug development.

Our comprehensive range of biospecimens may include:

If you have any questions, concerns, or special requests, please don’t hesitate to contact us.